参考文献
[1]Kandel ER，Schwartz JH，Jessell TM.Principles of Neural Science.Volume 4.New York：McGraw-Hill，2000.
[2]Dubois LG，Campanati L，Righy C，et al.Gliomas and the vascular fragility of the blood brain barrier.Front Cell Neurosci，2014，8：418.
[3]Kulik T，Kusano Y，Aronhime S，et al.Regulation of cerebral vasculature in normal and ischemic brain.Neuropharmacology，2008，55（3）：281-288.
[4]Jia ZZ，Gu HM，Zhou XJ，et al.The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging.Eur J Radiol，2015，84（9）：1805-1809.
[5]Haris M，Gupta RK，Singh A，et al.Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI.Neuroradiology，2008 ； 50（6）：531-540.
[6]Cha S，Knopp EA，Johnson G，et al.Intracranial mass lesions：dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.Radiology，2002，223（1）：11-29.
[7]Jung BC，Arevalo-Perez J，Lyo JK，et al.Comparison of Glioblastomas and Brain Metastases using Dynamic Contrast-Enhanced Perfusion MRI.J Neuroimaging，2016，26（2）：240-246.
[8]Murayama K，Nishiyama Y，Hirose Y，et al.Differentiating between central nervous system lymphoma and high-grade glioma using dynamic susceptibility contrast and dynamic contrast-enhanced mr imaging with histogram analysis.Magn Reson Med Sci，2018，17（1）：42-49.
[9]Lin X，Lee M，Buck O，et al.Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWIADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.Am J Neuroradiol，2017，38（3）：485-491.
[10]Hussain NS，Moisi MD，Keogh B，et al.Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.J Neurosurg，2017，126（4）：1220-1226.
[11]Artzi M，Liberman G，Blumenthal DT，et al.Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis.J Magn Reson Imaging，2018 Jan 3.[Epub ahead of print]
[12]Awasthi R，Rathore RK，Soni P，et al.Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers.Neuroradiology，2012，54（3）：205-213.
[13]Nguyen TB，Cron GO，Mercier JF，et al.Diagnostic accuracy of dynamic contrast-enhanced MR imaging using a phase-derived vascular input function in the preoperative grading of gliomas.Am J Neuroradiol，2012，33（8）：1539-1545.
[14]Arevalo-Perez J，Kebede AA，Peck KK，et al.Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas.J Neuroimaging，2016，26（3）：366-371.
[15]Keil VC，Pintea B，Gielen GH，et al.Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma：a prospective double-blinded evaluation of selection benefits.J Neurooncol，2017，133（1）：155-163.
[16]Zhao J，Yang ZY，Luo BN，et al.Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors.PLoS One，2015，10（9）：e0138573.
[17]Dhermain F，Saliou G，Parker F，et al.Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas.J Neurooncol，2010，97（1）：81-88.
[18]Jain R，Narang J，Griffith B，et al.Prognostic vascular imaging biomarkers in high-grade gliomas：tumor permeability as an adjunct to blood volume estimates.Acad Radiol，2013，20（4）：478-485.
[19]Kim R，Choi SH，Yun TJ，et al.Prognosis prediction of non-enhancing T2high signal intensity lesions in glioblastoma patients after standard treatment：application of dynamic contrast-enhanced MR imaging.Eur Radiol，2017，27（3）：1176-1185.
[20]Ulyte A，Katsaros VK，Liouta E，et al.Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.Neuroradiology，2016，58（12）：1197-1208.
[21]Burth S，Kickingereder P，Eidel O，et al.Clinical parameters outweigh diffusion-and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Neuro Oncol，2016，18（12）：1673-1679.
[22]Norden AD，Drappatz J，Muzikansky A，et al.An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.J Neurooncol，2009，92（2）：149-155.
[23]Batchelor TT，Sorensen AG，di Tomaso E，et al.AZD2171，a pan-VEGF receptor tyrosine kinase inhibitor，normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell，2007，11（1）：83-95.
[24]Di N，Yao C，Cheng W，et al.Correlation of dynamic contrast-enhanced MRI derived volume transfer constant with histological angiogenic markers in high-grade gliomas.J Med Imaging Radiat Oncol，2018 Jan 13.[Epub ahead of print]
[25]Chen X，Xie T，Fang J，et al.Quantitative in vivo imaging of tissue factor expression in glioma using dynamic contrast-enhanced MRI derived parameters.Eur J Radiol，2017，93：236-242.
[26]Sorensen AG，Batchelor TT，Zhang WT，et al.A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Cancer Res，2009，69（13）：5296-5300.
[27]Piludu F，Marzi S，Pace A，et al.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.Neuroradiology，2015，57（12）：1269-1280.
[28]Hygino da Cruz LC Jr，Rodriguez I，Domingues RC，et al.Pseudoprogression and pseudoresponse：imaging challenges in the assessment of posttreatment glioma.Am J Neuroradiol，2011，32（11）：1978-1985.
[29]Suh CH，Kim HS，Choi YJ，et al.Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.Am J Neuroradiol，2013，34（12）：2278-2286.
[30]Bisdas S，Naegele T，Ritz R，et al.Distinguishing recurrent high-grade gliomas from radiation injury：a pilot study using dynamic contrast-enhanced MR imaging.Acad Radiol，2011，18（5）：575-583.
[31]Thomas AA，Arevalo-Perez J，Kaley T，et al.Dynamic contrast enhanced T1MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.J Neurooncol，2015，125（1）：183-190.
[32]Shimohata T，Kanazawa M，Kawamura K，et al.Therapeutic strategies to attenuate hemorrhagic transformation after tissue plasminogen activator treatment for acute ischemic stroke.Neurology and Clinical Neuroscience，2013，1（6）：201-208.
[33]Khatri R，McKinney AM，Swenson B，et al.Blood-brain barrier，reperfusion injury，and hemorrhagic transformation in acute ischemic stroke.Neurology，2012，79（13）：S52-57.
[34]Hjort N，Wu O，Ashkanian M，et al.MRI detection of early blood-brain barrier disruption parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis.Stroke，2008 Mar； 39（3）：1025-1028.
[35]Campbell BC，Christensen S，Parsons MW，et al.Advanced imaging improves prediction of hemorrhage after stroke thrombolysis.Ann Neurol，2013 Apr； 73（4）：510-519.
[36]Bang OY，Buck BH，Saver JL，et al.Prediction of hemorrhagic transformation after recanalization therapy using T2∗-permeability magnetic resonance imaging.Ann Neurol.2007 ； 62（2）：170-176.
[37]Kassner A，Roberts T，Taylor K，et al.Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging.AJNR Am J Neuroradiol，2005，26（9）：2213-2217.
[38]Hoffmann A，Bredno J，Wendland MF，et al.Validation of in vivo magnetic resonance imaging blood-brain barrier permeability measurements by comparison with gold standard histology.Stroke，2011，42（7）：2054-2060.
[39]Krupinski J，Kaluza J，Kumar P，et al.Role of angiogenesis in patients with cerebral ischemic stroke.Stroke，1994，25（9）：1794-1798.
[40]Seevinck PR，Deddens LH，Di jkhuizen RM.Magnetic resonance imaging of brain angiogenesis after stroke.Angiogenesis，2010，13（2）：101-111.
[41]Lin CY，Chang C，Cheung WM，et al.Dynamic changes in vascular permeability，cerebral blood volume，vascular density，and size after transient focal cerebral ischemia in rats：evaluation with contrast-enhanced magnetic resonance imaging.J Cereb Blood Flow Metab，2008，28（8）：1491-1501.
[42]Ding G，Jiang Q，Li L，et al.Angiogenesis detected after embolic stroke in rat brain using magnetic resonance T2∗WI.Stroke，2008，39（5）：1563-1568.
[43]Li L，Jiang Q，Zhang L，et al.Ischemic cerebral tissue response to subventricular zone cell transplantation measured by iterative self-organizing data analysis technique algorithm.J Cereb Blood Flow Metab，2006，26（11）：1366-1377.
[44]Villringer K，Sanz Cuesta BE，Ostwaldt AC，et al.DCE-MRI blood-brain barrier assessment in acute ischemic stroke.Neurology，2017，88（5）：433-440.
[45]Pantoni L.Cerebral small vessel disease：from pathogenesis and clinical characteristics to therapeutic challenges.Lancet Neurol，2010，9（7）：689-701.
[46]Giwa MO，Williams J，Elderfield K，et al.Neuropathologic evidence of endothelial changes in cerebral small vessel disease.Neurology，2012，78（3）：167-174.
[47]Taheri S，Gasparovic C，Huisa BN，et al.Blood-brain barrier permeability abnormalities in vascular cognitive impairment.Stroke，2011，42（8）：2158-2163.
[48]Wardlaw JM，Doubal FN，Valdes-Hernandez M，et al.Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease.Stroke，2013，44（2）：525-527.
[49]Cramer SP，Simonsen H，Frederiksen JL，et al.Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI.Neuroimage Clin，2013，4：182-189.
[50]Cramer SP，Modvig S，Simonsen HJ，et al.Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis.Brain，2015，138（Pt 9）：2571-2583.